PRTA Earnings Date: Nov 5, 2026 (Estimated) — Prothena Corporation plc
NASDAQ · Healthcare · Biotechnology
Updated
When is PRTA's next earnings date?
Prothena Corporation plc (PRTA) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.23 on revenue of $9.6M.
How did PRTA do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Prothena Corporation plc posted EPS of -$0.36 versus the -$0.39 estimate, a beat of 256.5%. Revenue was $1.0M against a $421,667 estimate. The stock's 1-day post-earnings move was +2.1%.
How much does PRTA stock move after earnings?
PRTA beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.6% (up or down) in the day after earnings.
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.39 | -0.36 | -256.52% | $1.0M | ✅ Beat | +2.10% | +5.83% | +14.45% |
| 2026-05-07 | Q1 2026 | -0.31 | 0.60 | +293.55% | $51.1M | ✅ Beat | +2.00% | -6.27% | -18.63% |
| 2026-02-19 | Q4 2025 | -0.45 | -0.40 | +11.11% | $21,000 | ✅ Beat | -0.11% | -4.32% | -3.10% |
| 2025-11-06 | Q3 2025 | -0.56 | -0.68 | -21.43% | $2.4M | ❌ Miss | +4.76% | +0.99% | +6.45% |
| 2025-02-20 | Q4 2024 | -1.04 | -1.08 | -3.85% | $2.1M | ❌ Miss | +2.03% | -0.79% | -14.95% |
| 2024-11-12 | Q3 2024 | -1.18 | -1.10 | +6.78% | $970,000 | ✅ Beat | -0.75% | -19.07% | -20.45% |
| 2024-08-08 | Q2 2024 | -1.05 | 1.22 | +216.19% | $132.0M | ✅ Beat | +4.42% | +6.05% | +3.71% |
| 2024-05-08 | Q1 2024 | -1.20 | -1.34 | -11.67% | $50,000 | ❌ Miss | -4.47% | -2.78% | -8.25% |
Showing last 8 quarters.